Know Cancer

or
forgot password

A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life


N/A
21 Years
80 Years
Open (Enrolling)
Both
Newly Diagnosed Breast Cancer, Newly Diagnosed Colon Cancer, Newly Diagnosed Lung Cancer

Thank you

Trial Information

A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life


Inclusion Criteria:



- fluent in English, Spanish, or Mandarin

- between the ages of 21-80 years old

- In the Investigator's judgment, participants must have satisfactory cognitive
function to provide valid informed consent and participate in the ICCAN intervention.
The Blessed Orientation-Memory Concentration test (BOMC) will be used as a cognitive
screening tool. Patients must have a BOMC score of less than or equal to 11.

- has a new diagnosis of either breast, colon or lung cancer (diagnosed within the past
month) currently receiving chemotherapy (started within the past month) and/or
radiation therapy (started within the past week), or

- scheduled to begin chemotherapy and/or radiation therapy within the next 2 months
(excluding surgery only patients)

- planning on remaining in the area for at least 1 year

Exclusion Criteria:

- diagnosed with Stage IV disease

- presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to
preclude meaningful informed consent and/or data collection. (BOMC >11).

- has another family member already enrolled in ICCAN (as determined by patient report)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Treatment completion/adherence

Outcome Description:

The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Francesca Gany, MD, MS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

12-223

NCT ID:

NCT01742143

Start Date:

November 2012

Completion Date:

November 2014

Related Keywords:

  • Newly Diagnosed Breast Cancer
  • Newly Diagnosed Colon Cancer
  • Newly Diagnosed Lung Cancer
  • Quality of life
  • lung
  • breast
  • colon
  • 12-223
  • Breast Neoplasms
  • Colonic Neoplasms
  • Lung Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer Center New York, New York  10021
Lutheran Medical Center Brooklyn, New York  11220
Ralph Lauren Center for Cancer Care and Prevention New York, New York  10035
Lincoln Hospital Bronx, New York  10451